论文部分内容阅读
Fletcher A等于1959年首先应用链激酶治疗急性心肌梗塞,后因急性心肌梗塞与冠状动脉血栓的因果关系未定而使溶栓疗法搁置。近年资料证明约80％的急性心肌梗塞由冠状动脉内血栓形成所致。迅速恢复闭塞冠状动脉血流能及早供应缺血心肌足够的血液,缩小梗塞面积,改善泵功能,提高存活率。冠状动脉内输注链激酶治疗急性心肌梗塞疗效相当满意,但因必须冠状动脉内插管,不便普遍采用。本文旨在观察短期大剂量静脉输注尿激酶治疗急性心肌梗塞的临床效果。
Fletcher A was first treated with streptokinase in 1959 to treat acute myocardial infarction, and thrombolytic therapy was put on hold after the causal relationship between acute myocardial infarction and coronary thrombosis was undetermined. Recent data show that about 80% of acute myocardial infarction caused by coronary thrombosis. Rapid recovery of occluded coronary blood flow Early supply of enough blood to ischemic myocardium, reduce infarct size, improve pump function and improve survival. Coronary infusion streptokinase treatment of acute myocardial infarction is quite satisfactory, but due to the need for coronary intubation, inconvenience generally used. This article aims to observe the short-term high-dose intravenous infusion of urokinase in the treatment of acute myocardial infarction clinical effect.